Targeting phosphocreatine metabolism in relapsing–remitting multiple sclerosis: evaluation with brain MRI, 1 H and 31 P MRS, and clinical and cognitive testing

Melissa Cambron,Tatjana Reynders,Jan Debruyne,Harmen Reyngoudt,Annemie Ribbens,Erik Achten,Guy Laureys

Targeting phosphocreatine metabolism in relapsing–remitting multiple sclerosis: evaluation with brain MRI, 1 H and 31 P MRS, and clinical and cognitive testing

2018

Melissa Cambron
Tatjana Reynders
Jan Debruyne
Harmen Reyngoudt
Annemie Ribbens
Erik Achten
Guy Laureys

Background/objectives Fluoxetine and prucalopride might change phosphocreatine (PCr) levels via the cAMP–PKA pathway, an interesting target in the neurodegenerative mechanisms of MS.

Keywords:

Physical therapy
Cognitive test
Multiple sclerosis
Diabetes mellitus
Prucalopride
Phosphocreatine metabolism
Oncology
Medicine
Phosphocreatine
Internal medicine
Fluoxetine
White matter
Gastroenterology
Placebo
Grey matter
Magnetic resonance imaging

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations